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LETTERS TO EDITOR 
TETRABNAZINE FOR ISOLATED SHOULDER 
TARDIVE DYSKINESIA 
Sir, 
Tardive dyskinesia (TD) develops during 
exposure to neuroleptics or within four weeks of 
withdrawal from a neuroleptic. The most common 
features of TD are the involuntary movements of 
the oro-buccal, lingual, facial and limb muscles 
while purely truncal movements are less 
commonly observed. Treatment of TD is often 
unsatisfactory especially, in refractory cases and 
a large pharmacopoeia has been tried in this 
condition ranging from vitamins to mood 
stabilizers. None of these treatments, however, 
has consistently shown benefit in controlled trials 
(Ondo et al., 1999). We report the successful 
treatment with tetrabenazine of an isolated 
shoulder TD, an uncommon variety of TD, in a 
patient with schizophrenia. This drug has recently 
been launched in India (in 1999) and there are no 
reports of its efficacy in the Indian literature. 
TA, a 23-year-old, male with no contributory 
family history of mental or neurological illness, 
presented with an illness of five years duration 
characterized by suspiciousness, tearfulness, 
abusive and assaultive behaviour, feeling as if 
being controlled by external forces and 
unpredictable violence towards family members 
in response to command hallucinations. He was 
diagnosed with paranoid schizophrenia. Currently, 
the patient had a relapse following discontinuation 
of medicines. He was being treated with typical 
antipsychotics for the last four years and had 
shown improvement on medications but 
compliance had remained a problem. Over the 
last two years, while on medication, he developed 
an alternating rotatory movement of both the 
shoulders. He was having 50-60 such movements 
per minute, which resulted in severe subjective 
discomfort. The movements were involuntary, 
repetitive, purposeless, worsened with voluntary 
movements of other parts of the body and improved 
with relaxation and sleep. There were no 
associated oral or perioral movements or any other 
movements over the extremities. The patient 
underwent a CT scan of the brain, which was 
normal, and other causes for this presentation 
were excluded by relevant laboratory 
investigations. A possibility of isolated shoulder 
TD was entertained, though initially we were 
tempted to regard it as a stereotypic motor 
phenomenon encompassing the schizophrenic 
psychopathology. 
He was started on risperidone gradually 
increased up to 6 mg/day. An Abnormal 
Involuntary Movement Scale (AIMS) rating revealed 
a score of 12. The patient was then put on 
tetrabenazine 25 mg/day in divided doses and 
weekly AIMS were administered. Three weeks 
after commencing tetrabenazine, the AIMS rating 
came down to three, an improvement of 75%. 
Meanwhile, his psychopathology too improved and 
he was discharged after six weeks of in-patient 
stay. On follow-up after two months, the patient 
was completely free of TD and was continuing on 
risperidone 6 mg/day and tetrabenazine at 25 mg/ 
day. The tetrabenazine was discontinued in the 
next follow-up, without the re-emergence of the 
dyskinetic movements. The patient is currently 
on 4 mg of Resperidone and is symptom free, he 
comes for regular follow-up more than years after 
the first contact. 
We are not aware of any incidence figures 
for isolated shoulder TD and a medline search 
using the key words 'tardive dyskinesia' and 
'shoulder' was unyielding. Nevertheless, this 
appears to'be a rare form of TD as most patients 
with truncal TD have associated limb TD (Brown 
& White, 1992). Moreover, the uncommon truncal 
forms may be mistaken for stereotypies typical 
of schizophrenia. 
Besides highlighting the uncommon 
presentation of TD, we also call to attention the 
complete recovery of TD of two years duration with 
tetrabenazine. Tetrabenazine inhibits presynaptic 
dopamine release and blocks post-synaptic 
dopamine receptors It has been used for decades 
in neurology to treat hyperkinetic movement 
disorder including, dystonia, chorea, tics and other 
dyskinesias, (Jankovic & Orman, 1988). Similarly, 
its use in tardive dyskinesia dates back to early 
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60's (Brandup, 1961) with few reports scattered 
in each subsequent decade. However, there has 
been a resurgence of interest in this drug in recent 
years (Sachdev, 2000; Ondoetal., 1999; Jankovic 
& Beach, 1997), a probable consequence of failure 
of other heuristic approaches to deliver the goods. 
To conclude, given the dramatic benefit 
shown in this case and the relatively poor efficacy 
of traditional treatments for TD, it is felt that 
tetrabenazine should be considered in all cases 
of severe and refractory TD. However, a caveat is 
the occurrence of adverse effects such as 
sedation, Parkinsonism, insomnia, akathisiaand 
depression, which may limit its use. Long-term 
systematic studies are encouraged to address 
this issue as well as to ascertain efficacy in Indian 
population. Moreover, Indian patients may require 
comparatively lower doses of tetrabenazine than 
their western counterparts, as indicated by our 
patient's response to a dose of 25 mg/day, which 
is considered to be the starting dose (Ondo et 
al., 1999). Hence, future trials with this drug are 
desirable. 
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* Correspondence 
IN THE AFTERMATH OF ERWADI INCIDENT 
Sir, 
At Erwadi, a religious place in Tamilnadu, 
28 mentally ill persons lost their lives in a fire 
accident, because they were kept chained. 
Following that there have been significant steps 
taken by the State Government for the welfare of 
the mentally ill persons. These include closure 
of spurious centres that claim to treat and care 
for the mentally ill, enhancing the availability of 
psychiatrists in district hospitals, initiating action 
to implement National Mental Health Programme 
etc. Central Govt., on its part, has questioned 
State Governments on the implementation of 
the Mental Health Act '87. National Human 
Rights Commission started serious enquiries 
into the state of affairs of mentally ill. While 
all these are necessary and laudable efforts, 
we, as Psychiatrists, shouid also keep in mind 
two elements extremely important to the 
improvement of mental health care. 
1. Effective treatment 
Apart from the beliefs in religious 
remedies, the prevailing discrimination against 
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